44 reports of this reaction
2.0% of all FLUMAZENIL reports
#12 most reported adverse reaction
DRUG WITHDRAWAL CONVULSIONS is the #12 most commonly reported adverse reaction for FLUMAZENIL, manufactured by Baxter Healthcare Corporation. There are 44 FDA adverse event reports linking FLUMAZENIL to DRUG WITHDRAWAL CONVULSIONS. This represents approximately 2.0% of all 2,155 adverse event reports for this drug.
Patients taking FLUMAZENIL who experience drug withdrawal convulsions should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG WITHDRAWAL CONVULSIONS is a less commonly reported adverse event for FLUMAZENIL, but still significant enough to appear in the safety profile.
In addition to drug withdrawal convulsions, the following adverse reactions have been reported for FLUMAZENIL:
The following drugs have also been linked to drug withdrawal convulsions in FDA adverse event reports:
DRUG WITHDRAWAL CONVULSIONS has been reported as an adverse event in 44 FDA reports for FLUMAZENIL. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG WITHDRAWAL CONVULSIONS accounts for approximately 2.0% of all adverse event reports for FLUMAZENIL, making it a notable side effect.
If you experience drug withdrawal convulsions while taking FLUMAZENIL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.